Literature DB >> 7577933

Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.

G Tian1, R A Mook, M L Moss, S V Frye.   

Abstract

Finasteride (17 beta-N-tert-butylcarbamoyl-4-aza-5 alpha-androstan-1-en-3- one) is a time-dependent, apparently irreversible inhibitor of 5 alpha-reductases, but does not fully inhibit the activity of 5 alpha-reductase in vivo. This limited efficacy has been attributed to its slow rate of inhibition against the type-1 isozyme [Tian, G. (1995) J. Pharm. Sci. (in press)]. Here the feasibility of increasing the rate of inhibition of 5 alpha-reductases by providing binding energies with the inhibitor at a site remote from the center of chemical transformation was explored. Substitution of N-(2,5-bis(trifluoromethyl)phenyl) group, which had been shown to benefit 6-azasteroids in the binding to 5 alpha-reductases [Frye, S., Haffner, C. D., Maloney, P. R., Hiner, R. N., Unwalla, R. J., Batchelor, K. W., Bramson, H. N., Stuart, J. D., Schweiker, S. L., Van Arnold, J., Bickett, D. M., Moss, M. L., Tian, G., Lee, F. W., Tippin, T. K., James, M. K., Grizzle, M. K., Long, J. E., & Croom, D. K. (1995) J. Med. Chem. 38, 2621-2627], for the N-tert-butyl substituent at C-17 of finasteride did not perturb the mechanism of inhibition but significantly increased the rate of inhibition of type-1 5 alpha-reductase. The rate of inhibition was too fast to determine accurately when the normal substrate testosterone was used in the progress curve analysis as this inhibition rate is approaching the value of kcat/Km for the enzyme reaction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7577933     DOI: 10.1021/bi00041a024

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.

Authors:  P O Gisleskog; D Hermann; M Hammarlund-Udenaes; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

2.  5α-reductase type 3 enzyme in benign and malignant prostate.

Authors:  Mark A Titus; Yun Li; Olga G Kozyreva; Varun Maher; Alejandro Godoy; Gary J Smith; James L Mohler
Journal:  Prostate       Date:  2013-10-22       Impact factor: 4.104

Review 3.  Medical treatment of benign prostatic hyperplasia.

Authors:  Stephen S Connolly; John M Fitzpatrick
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

Review 4.  Dutasteride.

Authors:  Hannah C Evans; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Benign prostatic hyperplasia: An overview of existing treatment.

Authors:  Neelima Dhingra; Deepak Bhagwat
Journal:  Indian J Pharmacol       Date:  2011-02       Impact factor: 1.200

6.  Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.

Authors:  Jin Li; Zhiyong Ding; Zhengxin Wang; Jing-Fang Lu; Sankar N Maity; Nora M Navone; Christopher J Logothetis; Gordon B Mills; Jeri Kim
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

7.  Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception.

Authors:  Samuel J Pellock; Benjamin C Creekmore; William G Walton; Naimee Mehta; Kristen A Biernat; Andrew P Cesmat; Yamuna Ariyarathna; Zachary D Dunn; Bo Li; Jian Jin; Lindsey I James; Matthew R Redinbo
Journal:  ACS Cent Sci       Date:  2018-07-12       Impact factor: 14.553

8.  Structure of human steroid 5α-reductase 2 with anti-androgen drug finasteride.

Authors:  Qingpin Xiao; Lei Wang; Shreyas Supekar; Tao Shen; Heng Liu; Fei Ye; Junzhou Huang; Hao Fan; Zhiyi Wei; Cheng Zhang
Journal:  Res Sq       Date:  2020-07-15

9.  Crystal structure of (20S)-21-[4-(2-hy-droxy-propan-2-yl)-1H-1,2,3-triazol-4-yl]-20-(4-methyl-pent-yl)-5-pregnen-3β-ol with an unknown solvate.

Authors:  Hugo Santalla; Saray Argibay
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2018-03-06

10.  The Steroidogenesis Inhibitor Finasteride Reduces the Response to Both Stressful and Rewarding Stimuli.

Authors:  Sean C Godar; Roberto Cadeddu; Gabriele Floris; Laura J Mosher; Zhen Mi; David P Jarmolowicz; Simona Scheggi; Alicia A Walf; Carolyn J Koonce; Cheryl A Frye; Nancy A Muma; Marco Bortolato
Journal:  Biomolecules       Date:  2019-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.